Lung Neuroendocrine Neoplasm

subtype

Identifier: CI-CAN-00001096
Entity page: /cancer/lung-neuroendocrine-neoplasm ↗
Edges: 1,343

Neighbours: 44 genes15 drugs10 trials
Drawn: 60 of 69 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Lung Neuroendocrine Neoplasm approved for …APPROVED_FORderived15 of 15
← approved for	Tarlatamabmonoclonal antibody EMA (EU) · approved · 2026-05-29 · Imdylltra is indicated as monotherapy for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), who requir…	—	approved	Lung Small Cell Carcinoma	1	Regulatory	ema	graph →
← approved for

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

RB1 Mutation Chemotherapy8 active / 12 trials
Curatedlevel Bsensitivity· support 1civicObservedRB1 altered in 73% (87 / 120 cases)no approval record in this cancercontext: Lung Small Cell Carcinoma
ERBB2 Amplification Irinotecan7 active / 35 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: Lung Small Cell Carcinoma
ERBB2 Amplification Trastuzumab0 active / 1 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: Lung Small Cell Carcinoma
CHEK1 Overexpression Cisplatin20 active / 74 trials
Curatedlevel Dsensitivity· support 1civicObservedcohort frequency not yet available for CHEK1 in this cancerno approval record in this cancercontext: Lung Small Cell Carcinoma
CHEK1 Overexpression Olaparib6 active / 13 trials
Curatedlevel Dsensitivity· support 1civicObservedcohort frequency not yet available for CHEK1 in this cancerno approval record in this cancercontext: Lung Small Cell Carcinoma
CHEK1 Overexpression Prexasertib0 active / 1 trials
Curatedlevel Dsensitivity· support 1civicObservedcohort frequency not yet available for CHEK1 in this cancerno approval record in this cancercontext: Lung Small Cell Carcinoma
EGFR L858R Erlotinib0 active / 2 trials
Curatedlevel Dsensitivity· support 1civicObservedcohort frequency not yet available for EGFR in this cancerno approval record in this cancercontext: Lung Small Cell Carcinoma
MYC Overexpression Cisplatin20 active / 74 trials
Curatedlevel Dsensitivity· support 1civicObservedcohort frequency not yet available for MYC in this cancerno approval record in this cancercontext: Lung Small Cell Carcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Lung Neuroendocrine Neoplasm altered in cohorts of …ALTERED_INderived44 of 44show fewer
← altered in cohorts of	POLE 20 / 20 cases (100 %) · ssm · sclc_cancercell_gardner_2017	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	TP53 103 / 120 cases (86 %) · ssm · sclc_ucologne_2015 · largest of 3 cohorts	—	—	Lung Small Cell Carcinoma	3	Observed	cbioportal	graph →
← altered in cohorts of	RB1 87 / 120 cases (73 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	TTN 77 / 120 cases (64 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	RYR2 54 / 120 cases (45 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	LRP1B 51 / 120 cases (43 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	MUC16 49 / 120 cases (41 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	ZFHX4 46 / 120 cases (38 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	USH2A 44 / 120 cases (37 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	CSMD3 42 / 120 cases (35 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	NAV3 35 / 120 cases (29 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	PCDH15 32 / 120 cases (27 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	COL11A1 31 / 120 cases (26 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	CSMD1 28 / 120 cases (23 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	EYS 27 / 120 cases (23 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	MUC17 27 / 120 cases (23 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	SYNE1 27 / 120 cases (23 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	ANKRD30B 26 / 120 cases (22 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	FAM135B 26 / 120 cases (22 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	FSIP2 25 / 120 cases (21 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	TMEM132D 25 / 120 cases (21 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	ERICH3 24 / 120 cases (20 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	PKHD1 24 / 120 cases (20 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	SI 24 / 120 cases (20 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	PKHD1L1 23 / 120 cases (19 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	RYR1 23 / 120 cases (19 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	SPTA1 23 / 120 cases (19 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	TENM1 23 / 120 cases (19 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	XIRP2 23 / 120 cases (19 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	ADGB 22 / 120 cases (18 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	FAT3 22 / 120 cases (18 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	KMT2D 22 / 120 cases (18 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	NCAM2 22 / 120 cases (18 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	RYR3 22 / 120 cases (18 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	TNR 22 / 120 cases (18 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	DMD 21 / 120 cases (18 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	HCN1 21 / 120 cases (18 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	PCLO 21 / 120 cases (18 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	COL22A1 20 / 120 cases (17 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	CSMD2 20 / 120 cases (17 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	DNAH5 20 / 120 cases (17 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	FMN2 20 / 120 cases (17 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	SPHKAP 20 / 120 cases (17 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	ZNF729 20 / 120 cases (17 %) · ssm · sclc_ucologne_2015	—	—	Lung Small Cell Carcinoma	1	Observed	cbioportal	graph →

Lung Neuroendocrine Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 135show all (up to 200)
→ investigated in trials for	Etoposidesmall molecule 131 trials (50 active) · roll-up of the cancer and its descendants	—	—	Lung Neuroendocrine Neoplasm	131	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 117 trials (42 active) · roll-up of the cancer and its descendants	—	—	Lung Neuroendocrine Neoplasm	117	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 74 trials (20 active) · roll-up of the cancer and its descendants	—	—	Lung Neuroendocrine Neoplasm	74	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 63 trials (23 active) · roll-up of the cancer and its descendants	—	—	Lung Neuroendocrine Neoplasm	63	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 59 trials (35 active) · roll-up of the cancer and its descendants	—	—	Lung Neuroendocrine Neoplasm	59	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 54 trials (36 active) · roll-up of the cancer and its descendants	—	—	Lung Neuroendocrine Neoplasm	54	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 36 trials (11 active) · roll-up of the cancer and its descendants	—	—	Lung Neuroendocrine Neoplasm	36	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 35 trials (7 active) · roll-up of the cancer and its descendants	—	—	Lung Neuroendocrine Neoplasm	35	Observed	clinicaltrials	graph →
→ investigated in trials for	Lurbinectedinsmall molecule 29 trials (20 active) · roll-up of the cancer and its descendants	—	—	Lung Neuroendocrine Neoplasm	29	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 25 trials (8 active) · roll-up of the cancer and its descendants	—	—	Lung Neuroendocrine Neoplasm	25	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 23 trials (11 active) · roll-up of the cancer and its descendants	—	—	Lung Neuroendocrine Neoplasm	23	Observed	clinicaltrials	graph →
→ investigated in trials for	Tarlatamabmonoclonal antibody 23 trials (20 active) · roll-up of the cancer and its descendants	—	—	Lung Neuroendocrine Neoplasm	23	Observed	clinicaltrials	graph →
→ investigated in trials for	Adebrelimabmonoclonal antibody 19 trials (14 active) · roll-up of the cancer and its descendants	—	—	Lung Neuroendocrine Neoplasm	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal antibody 16 trials (5 active) · roll-up of the cancer and its descendants	—	—	Lung Neuroendocrine Neoplasm	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Temozolomidesmall molecule 15 trials (6 active) · roll-up of the cancer and its descendants	—	—	Lung Neuroendocrine Neoplasm	15	Observed	clinicaltrials	graph →

Lung Neuroendocrine Neoplasm studied in …STUDIED_INderived10 of 1,149show all (up to 200)
→ studied in	NCT02146170recruiting Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors · condition mapped ALIAS · 1,149 trials mapped (456 active)	—	—	Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06586957Phase 1 · recruiting A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors · condition mapped ALIAS · 1,149 trials mapped (456 active)	—	—	Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07226999Phase 2/Phase 3 · recruiting Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer · condition mapped ALIAS · 1,149 trials mapped (456 active)	—	—	Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07476287Phase 2 · recruiting Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer · condition mapped ALIAS · 1,149 trials mapped (456 active)	—	—	Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07509034Phase 1 · recruiting Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease · condition mapped CURATED_BROADER · 1,149 trials mapped (456 active)	—	—	Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07843940Phase 1/Phase 2 · not yet recruiting A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) · condition mapped CURATED_BROADER · 1,149 trials mapped (456 active)	—	—	Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02498613Phase 2 · active not recruiting A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors · condition mapped CURATED_BROADER · 1,149 trials mapped (456 active)	—	—	Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02595931Phase 1 · active not recruiting M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery · condition mapped CURATED_BROADER · 1,149 trials mapped (456 active)	—	—	Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03460977Phase 1 · recruiting A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma · condition mapped ALIAS · 1,149 trials mapped (456 active)	—	—	Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07037758Phase 1 · recruiting A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) · condition mapped CURATED_BROADER · 1,149 trials mapped (456 active)	—	—	Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →